Higher CSF sTREM2 and microglia activation are associated with slower rates of beta-amyloid accumulation
Open accessThe DOI matches its Crossref record; 93 of the 94 references it cites were found in a registry or an index.
Abstract
Microglia activation is the brain's major immune response to amyloid plaques in Alzheimer's disease (AD). Both cerebrospinal fluid (CSF) levels of soluble TREM2 (sTREM2), a biomarker of microglia activation, and microglia PET are increased in AD; however, whether an increase in these biomarkers is associated with reduced amyloid‐beta (Aβ) accumulation remains unclear. To address this question, we pursued a two‐pronged translational approach. Firstly, in non‐demented and demented individuals, we tested CSF sTREM2 at baseline to predict (i) amyloid PET changes over ∼2 years and (ii) tau PET cross‐sectionally assessed in a subset of patients. We found higher CSF sTREM2 associated with attenuated amyloid PET increase and lower tau PET. Secondly, in the App NL‐G-F mouse model of amyloidosis, we studied baseline 18 F‐GE180 microglia PET and longitudinal amyloid PET to test the microglia vs. Aβ association, without any confounding co‐pathologies often present in AD patients. Higher microglia PET at age 5 months was associated with a slower amyloid PET increase between ages 5‐to‐10 months. In conclusion, higher microglia activation as determined by CSF sTREM2 or microglia PET shows protective effects on subsequent amyloid accumulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, microglial activation may also be protective in these neurodegenerative conditions, for example by enhancing microglia phagocytosis of amyloid plaques in the context of AD (176–178).”
From Connecting aging biology and inflammation in the omics era (2022) · cites this paper as [177]
In the citing paper
“High CSF sTREM2 was associated with slower rates of Aβ accumulation”
From Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets (2023) · cites this paper as [187]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“The deposition of amyloid-b (Ab) peptide is a key primary alteration that defines Alzheimer’s disease (AD), involving a cascade of pathological brain changes resulting in the occurrence of dementia symptoms (Hardy & Higgins, 1992; Selkoe & Hardy, 2016).”
BackgroundThe amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 1×
“The deposition of amyloid-b (Ab) peptide is a key primary alteration that defines Alzheimer’s disease (AD), involving a cascade of pathological brain changes resulting in the occurrence of dementia symptoms (Hardy & Higgins, 1992; Selkoe & Hardy, 2016).”
BackgroundA Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 1×
“In 5×FAD mice which show Ab deposition in the hippocampus and cortex by 6 months of age (Oakley et al, 2006), knockdown of the TREM2 gene decreased microglia activation but increased amyloid plaque load at ages 8 months in the hippocampus (Wang et al, 2015) and cortex (Griciuc et al, 2019).”
BackgroundComplement and microglia mediate early synapse loss in Alzheimer mouse models
Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K. M., Shi, Q., Rosenthal, A., Barres, B. A., et al. (2016) · Science · doi:10.1126/science.aad8373 · Cited by 3,343 · cited 1×
“However, microglia activation can also be detrimental by inducing neurotoxic inflammation (Meda et al, 1995; Hong et al, 2016).”
BackgroundHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Self-citationTREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020 · cited 1×
“…that alterations in the innate immune system are associated with enhanced risk of AD and thus modulate the development of AD (Lambert et al, 2009; Guerreiro et al, 2013; Jonsson et al, 2013; Reitz et al, 2013; Efthymiou & Goate, 2017; Sims 1 Institute for Stroke and Dementia Research (ISD),…”
BackgroundSelf-citationKrasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R., Beckers, L., O’Loughlin, E., Xu, Y., Fanek, Z., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.008 · Cited by 2,979 · cited 2×
“TREM2 activation increases the ApoE-dependent phenotypic switch from a homeostatic to a disease-associated microglial signature in response to Ab (Krasemann et al, 2017; Parhizkar et al, 2019).”
BackgroundSelf-citationAlzheimer's Disease Neuroimaging Initiative (ADNI)
Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cb3e25 · Cited by 2,572 · cited 1×
“…normal (CN, MMSE > 24, CDR = 0, non-depressed), mild cognitively impaired (MCI; MMSE > 24, CDR = 0.5, objective memory-loss on the education adjusted Wechsler Memory Scale II, preserved activities of daily living) or AD dementia following standard diagnostic criteria (Petersen et al, 2010).”
InfluentialSelf-citation
Cited by
Items 101–135 of 135
Bonomi, C. G., Chiaravalloti, A., Camedda, R., Ricci, F., Mercuri, N. B., Schillaci, O., Koch, G., Martorana, A., & Motta, C. (2023) · Biomedicines · doi:10.3390/biomedicines11030725 · Cited by 6
Li, A., Initiative, A. D. N., Du, J., Cai, Y. Q., Chen, X., Sun, K., & Guo, T. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230446 · Cited by 5
Fluid Biomarkers in Clinical Trials for Alzheimer’s Disease: Current and Future Application
Yang, J., Jia, L., Li, Y., Qiu, Q., Quan, M., & Jia, J. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201068 · Cited by 5
Yu, J., Bao, X., Shan, C., Yu, Z., Yu, Y., Wang, H., & Zhang, Y. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1691253 · Cited by 3
Kunze, L. H., Palumbo, G., Gnörich, J. S., Wind-Mark, K., Schaefer, R., Lindner, S., Gildehaus, F. J., Ziegler, S., & Brendel, M. (2025) · NeuroImage · doi:10.1016/j.neuroimage.2025.121165 · Cited by 6
Self-citationCD33 and clusterin interact biophysically and genetically to modulate Alzheimer risk
Dodd, R. B., Enomoto, M., Zhou, Y., Satoh, K., Zhang, Y., Chen, F., Acheson, B., Ghaffari, D., Sayn-Wittgenstein, E., Manning, J. J., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-75140-3 · Cited by 6
Pre-therapeutic Microglia Activation and Sex Determine Therapy Effects of Chronic ImmunomodulationPreprint
Biechele, G., Blume, T., Deußing, M., Zott, B., Shi, Y., Xiang, X., Franzmeier, N., Kleinberger, G., Peters, F., Ochs, K., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.30.445761 · Cited by 3
Self-citationCell autonomous microglia defects in a stem cell model of frontotemporal dementiaPreprint
Iyer, A. K., Vermunt, L., Mirfakhar, F. S., Minaya, M., Acquarone, M., Koppisetti, R. K., Renganathan, A., You, S., Danhash, E., Verbeck, A. C., et al. (2024) · medRxiv · doi:10.1101/2024.05.15.24307444 · Cited by 3
GLP-1 agonists in neurodegeneration: a multimodal biomarker-guided approach
Santiago, J. A., Gutierrez-Silva, J. C., Hsu, W.-C., Sanchez, K., Almanza, C., Ramos, W., Haq, I. U., & Rundek, T. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.12.001 · Cited by 4
Peng, T., Zhang, Z., Ding, N., & Zhang, J. (2026) · Neural Plasticity · doi:10.1155/np/6718671 · Cited by 2
Ma, J., Yang, B., Jiang, X., Wang, L., Wei, W., Cao, Y., & Li, H. (2026) · Experimental Gerontology · doi:10.1016/j.exger.2026.113177 · Cited by 4
Qian, S., Zheng, Y., Jiang, T., Hou, J., Cao, R., Cai, J., Ma, E., Wang, W., Song, W., & Xie, C. (2024) · The Journals of Gerontology Series A · doi:10.1093/gerona/glae185 · Cited by 2
Biel, D., Suárez‐Calvet, M., Hager, P., Rubinski, A., Dewenter, A., Steward, A., Roemer, S. N., Ewers, M., Haass, C., Brendel, M., et al. (2022) · medRxiv · doi:10.1101/2022.08.26.22279269 · Cited by 2
Self-citationThe fluid biomarkers of Alzheimer’s disease
Peng, Q., & Zhang, Z. (2021) · Brain Science Advances · doi:10.26599/bsa.2021.9050001 · Cited by 1
sTREM2 in discordant CSF Aβ42 and p‐tau181
Li, D., Mantyh, W. G., Men, L., Jain, I., Glittenberg, M., An, B., Zhang, L., Li, L., & Initiative, A. D. N. (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70072 · Cited by 2
Yu, R., Suraev, A. S., Vidal, V., Kong, S. D., Zachariae, R. H., Piccio, L. M., Heneka, M. T., Naismith, S. L., & Michaelian, J. C. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03787-x · Cited by 1
Self-citationXu, X., Fan, S.-S., Wu, H., Du, Y., Bo, Y., He, J., He, Y., Cheng, N., & Meng, X. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-04280-3 · Cited by 1
Fawzy, M. N. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02363-7 · Cited by 2
Microglia, TREM2, and Therapeutic Methods of Alzheimer’s Disease
Xu, S., Ji, Y., Sha, T., & Li, H. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100203
de Weerd, L., Hummel, S., Müller, S. A., Paris, I., Sandmann, T., Eichholtz, M., Gröger, R., Englert, A. L., Wagner, S., Ha, C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.10.645950
Self-citationFluid and Imaging Markers of Glial Reactivity
Suárez‐Calvet, M. (2025) · Springer eBooks · doi:10.1007/978-3-031-80849-4_6 · Cited by 1
Self-citationWang, L., Nykänen, N.-P., Western, D., Gorijala, P., Timsina, J., Li, F., Wang, Z., Ali, M., Yang, C., Liu, M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.24940635
Self-citationFranzmeier, N., Suárez‐Calvet, M., Frontzkowski, L. K., Moore, A. M., Hohman, T. J., Morenas‐Rodríguez, E., Nuscher, B., Shaw, L. M. J., Trojanowski, J. Q., Dichgans, M., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13071124
Self-citationZatcepin, A., Gnörich, J. S., Rauchmann, B.-S., Bartos, L. M., Wagner, S., Franzmeier, N., Malpetti, M., Xiang, X., Shi, Y., Parhizkar, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26952306
Self-citationWang, L., Nykänen, N.-P., Western, D., Gorijala, P., Timsina, J., Li, F., Wang, Z., Ali, M., Yang, C., Liu, M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.24940872
Self-citationWang, Y., Ye, M., Ji, Q., Liu, Q., Xu, X., & Zhan, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26739390
Winfree, R. L., Nolan, E., Dumitrescu, L., Blennow, K., Zetterberg, H., Gifford, K. A., Pechman, K. R., Seto, M., Petyuk, V. A., Wang, Y., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25852991
Xu, G., Xu, P., Lei, Y., Zhou, Z., Chen, Y., Zhan, J., Feng, F., Cai, Z., & Chen, F. (2026) · Alcohol and Alcoholism · doi:10.1093/alcalc/agag036
Clinical Indication of the Role of Inflammation in Alzheimer’s Disease
Kumar, A., Sarkar, N., Kundu, M., Singh, V., & Dasgupta, D. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898815646126010010
Wang, H., Wen, R., Parker, E., & Yang, L. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-03083-9 · Cited by 4
Cancer Hacks Neurodegeneration: Cystatin-C as a Bridge for Microglial Amyloid Clearance via TREM2
Zhang, Y., Li, C., & Li, C. (2026) · Research · doi:10.34133/research.1456
Before the insult: Why the microglial starting state matters in neurodegeneration
Szelechowski, M. (2026) · Glial health research. · doi:10.1016/j.ghres.2026.100022
Dejanovic, B., Figley, M. D., Weisman, E. F., Kiragasi, B., Gergits, F. W., Larson, K., Renoux, A. J., Rajagovindan, R., Pandya, B. A., Houze, J. B., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.aec5740 · Cited by 2
Zhao, X., He, J., Yu, W., Lin, H., He, Q., Zhenyan, S., & Cheng, S. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06281-1
Sandmann, T. (2025) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.14812454
Metadata
- Authors
- Ewers, M., Biechele, G., Suárez‐Calvet, M., Sacher, C., Blume, T., Morenas‐Rodriguez, E., Deming, Y., Piccio, L., Cruchaga, C., Kleinberger, G., Shaw, L., Trojanowski, J. Q., Herms, J., Dichgans, M., (ADNI), T. A. D. N. I., Brendel, M., Haass, C., & Franzmeier, N.
- Affiliations
- German Center for Neurodegenerative Diseases (DE)
- Ludwig-Maximilians-Universität München (DE)
- Pasqual Maragall Foundation (ES)
- University of Wisconsin–Madison (US)
- The University of Sydney (AU)
- Washington University in St. Louis (US)
- University of Pennsylvania (US)
- Institut für Schlaganfall- und Demenzforschung (DE)
- Corresponding author
- Ewers, Michael
- ORCID
- Venue
- EMBO Molecular Medicine
- Published
- 2020-08-10
- Volume
- 12
- Issue
- 9
- Pages
- e12308-e12308
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- PMC
- PMC7507349
- OpenAlex
- W3047911986
- Cited by
- 133
- References
- 94
- Citations by year
- 2026: 15 · 2025: 27 · 2024: 27 · 2023: 19 · 2022: 20 · 2021: 20 · 2020: 5
- FWCI
- 9.59
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- EMBO Molecular Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Repositori digital de la UPF (Universitat Pompeu Fabra) (acceptedVersion, cc-by)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion, cc-by)
- DZNE Pub (submittedVersion, cc-by)
- Funders
- LMUexcellent
- Deutsche Forschungsgemeinschaft (EXC 1010 SyNergy, HA1737/16-1)
- HHS | National Institutes of Health (U01 AG024904)
- U.S. Department of Defense (W81XWH-12-2-0012)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- soluble TREM2, cerebrospinal fluid biomarkers, microglial activation, amyloid-beta deposition, Alzheimer's disease, amyloid PET, tau PET, neuroinflammation, amyloid plaques
- MeSH terms
- Alzheimer Disease, Animals, Humans, Membrane Glycoproteins, Receptors, Immunologic, Biomarkers, Amyloid beta-Peptides, tau Proteins, Microglia, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.